<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341730</url>
  </required_header>
  <id_info>
    <org_study_id>CUKCVC</org_study_id>
    <nct_id>NCT01341730</nct_id>
  </id_info>
  <brief_title>The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT)</brief_title>
  <acronym>PIONEER</acronym>
  <official_title>Evaluation of the Effect of Atorvastatin and Pioglitazone in Carotid Atherosclerosis With the Use of 18Fluoride-Fludeoxyglucose(FDG) Positron Emission Tomography-computed Tomography (PET-CT)Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective randomized clinical trial and to compare the antiinflammatory&#xD;
      effect of atorvastatin single therapy and atorvastatin and pioglitazone combination therapy&#xD;
      in carotid arteries of stable and unstable angina patients by PET/CT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of Standardized Uptake Value (SUV) of Atherosclerotic Plaque in Carotid Artery by PET CT</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference PET CT Parameters in 3 Months Compared to Initial Evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>Change of Maximum Standardized Uptake Value (SUVmax),Mean Standardized Uptake Value (SUVmean)- no unit for this value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of Laboratory Data Compared to Initial Evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>Change of high sensitivity C-reactive protein (hsCRP, mg/dl) Change of low density lipoprotein cholesterol(mg/dl) Change of high density lipoprotein cholesterol(mg/dl) Change of triglyceride (mg/dl) Change of matrix metalloproteinase 9 (mcg/ml) Change of plasminogen activator inhibitor (PAI)-1 (ng/ml) Change of Homeostatic Model Assessment (HOMA) index (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Incidents</measure>
    <time_frame>3 months</time_frame>
    <description>Major adverse cerebro-cardiovascular event: a composite of cardiac death, nonfatal myocardial infarction, stroke, and target vessel revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg&quot; group is to take atorvastatin 20 mg and take follow up PET CT in 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg + Pioglitazone 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg + Pioglitazone 30 mg&quot; group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20mg</intervention_name>
    <description>20 mg QD for 3 months</description>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <other_name>Lipitor 20mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20 mg + Pioglitazone 30 mg</intervention_name>
    <description>atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months</description>
    <arm_group_label>Atorvastatin 20 mg + Pioglitazone 30 mg</arm_group_label>
    <other_name>Lipitor 20mg plus Actos 30mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject who has undergone percutaneous coronary intervention due to coronary&#xD;
             artery disease ( stable angina or unstable angina)&#xD;
&#xD;
          -  The subject described above who has atherosclerotic plaque in his/her carotid artery&#xD;
             by carotid ultrasonography&#xD;
&#xD;
          -  The subject who or a legal representative agrees to the clinical trial and gives&#xD;
             written permission to the IRB-approved form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subjets who have taken statins or thiazolidinedione with 4 weeks&#xD;
&#xD;
          -  Marked elevated liver enzyme ( more than 2.5 fold compared to reference range)&#xD;
&#xD;
          -  Renal insufficiency patients ( serum creatinine more than 2 mg/dl)&#xD;
&#xD;
          -  Congestive heart failure ( NYHA class 2-4)&#xD;
&#xD;
          -  Acue myocardial infarction&#xD;
&#xD;
          -  Unstable angina with ST segment deviation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  The subjects enrolled in another studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiyuk Chang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Seoul St. Mary's hospital, The Catholic University of Korea, Colege of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular center, Seoul St. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2011</study_first_posted>
  <results_first_submitted>July 17, 2018</results_first_submitted>
  <results_first_submitted_qc>July 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2020</results_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Eun Ho Choo</investigator_full_name>
    <investigator_title>Cardiovascular Center, Seoul St. Mary's Hospital,</investigator_title>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Pioglitazone</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>PET CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was terminated prematurely due to slow enrollment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin 20 mg</title>
          <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg&quot; group is to take atorvastatin 20 mg and take follow up PET CT in 3 months&#xD;
Atorvastatin 20mg: 20 mg QD for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin 20 mg + Pioglitazone 30 mg</title>
          <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg + Pioglitazone 30 mg&quot; group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months&#xD;
Atorvastatin 20 mg + Pioglitazone 30 mg: atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Four patients from each group withdrew the consent after enrollment.</population>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin 20 mg</title>
          <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg&quot; group is to take atorvastatin 20 mg and take follow up PET CT in 3 months&#xD;
Atorvastatin 20mg: 20 mg QD for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin 20 mg + Pioglitazone 30 mg</title>
          <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg + Pioglitazone 30 mg&quot; group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months&#xD;
Atorvastatin 20 mg + Pioglitazone 30 mg: atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" spread="11.0"/>
                    <measurement group_id="B2" value="63.4" spread="10.5"/>
                    <measurement group_id="B3" value="63" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference of Standardized Uptake Value (SUV) of Atherosclerotic Plaque in Carotid Artery by PET CT</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 20 mg</title>
            <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg&quot; group is to take atorvastatin 20 mg and take follow up PET CT in 3 months&#xD;
Atorvastatin 20mg: 20 mg QD for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg + Pioglitazone 30 mg</title>
            <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg + Pioglitazone 30 mg&quot; group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months&#xD;
Atorvastatin 20 mg + Pioglitazone 30 mg: atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Difference of Standardized Uptake Value (SUV) of Atherosclerotic Plaque in Carotid Artery by PET CT</title>
          <units>standardized uptake value (SUV)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.04"/>
                    <measurement group_id="O2" value="-0.10" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference PET CT Parameters in 3 Months Compared to Initial Evaluation</title>
        <description>Change of Maximum Standardized Uptake Value (SUVmax),Mean Standardized Uptake Value (SUVmean)- no unit for this value</description>
        <time_frame>3 months</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 20 mg</title>
            <description>Data were not collected</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg + Pioglitazone 30 mg</title>
            <description>Data were not collected</description>
          </group>
        </group_list>
        <measure>
          <title>Difference PET CT Parameters in 3 Months Compared to Initial Evaluation</title>
          <description>Change of Maximum Standardized Uptake Value (SUVmax),Mean Standardized Uptake Value (SUVmean)- no unit for this value</description>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference of Laboratory Data Compared to Initial Evaluation</title>
        <description>Change of high sensitivity C-reactive protein (hsCRP, mg/dl) Change of low density lipoprotein cholesterol(mg/dl) Change of high density lipoprotein cholesterol(mg/dl) Change of triglyceride (mg/dl) Change of matrix metalloproteinase 9 (mcg/ml) Change of plasminogen activator inhibitor (PAI)-1 (ng/ml) Change of Homeostatic Model Assessment (HOMA) index (%)</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Incidents</title>
        <description>Major adverse cerebro-cardiovascular event: a composite of cardiac death, nonfatal myocardial infarction, stroke, and target vessel revascularization</description>
        <time_frame>3 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin 20 mg</title>
          <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg&quot; group is to take atorvastatin 20 mg and take follow up PET CT in 3 months&#xD;
Atorvastatin 20mg: 20 mg QD for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin 20 mg + Pioglitazone 30 mg</title>
          <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg + Pioglitazone 30 mg&quot; group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months&#xD;
Atorvastatin 20 mg + Pioglitazone 30 mg: atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eun Ho Choo</name_or_title>
      <organization>The Catholic University of Korea</organization>
      <phone>82-10-8500-4569</phone>
      <email>cmcchu@catholic.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

